{
    "id": 26494,
    "fullName": "AURKB positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "AURKB positive indicates the presence of AURKB gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9212,
        "geneSymbol": "AURKB",
        "terms": [
            "AURKB",
            "AIK2",
            "AIM-1",
            "AIM1",
            "ARK-2",
            "ARK2",
            "AurB",
            "aurkb-sv1",
            "aurkb-sv2",
            "IPL1",
            "PPP1R48",
            "STK-1",
            "STK12",
            "STK5"
        ]
    },
    "variant": "positive",
    "createDate": "04/26/2017",
    "updateDate": "05/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10679,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRD-7880 inhibited growth of a panel of cancer cell lines in culture with phenotype suggesting Aurora kinase B inhibition (PMID: 26928769).",
            "molecularProfile": {
                "id": 27721,
                "profileName": "AURKB positive"
            },
            "therapy": {
                "id": 5574,
                "therapyName": "BRD-7880",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8730,
                    "pubMedId": 26928769,
                    "title": "High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26928769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10687,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TY-011 inhibited activities of Aurora kinase A and Aurora kinase B, resulting in growth inhibition in culture and decrease tumor size and angiogenesis in cell line xenograft models of gastric cancer (PMID: 27887633).",
            "molecularProfile": {
                "id": 27730,
                "profileName": "AURKA pos AURKB pos"
            },
            "therapy": {
                "id": 5586,
                "therapyName": "TY-011",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8743,
                    "pubMedId": 27887633,
                    "title": "Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27887633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines positive for AURKA and AURKB were sensitive to SNS-314 in culture, demonstrating reduced cell proliferation, induced apoptotic activity, and suppression of YAP activity, a result of AURKA and AURKB inhibition, which led to P21 activity (PMID: 28427193).",
            "molecularProfile": {
                "id": 27730,
                "profileName": "AURKA pos AURKB pos"
            },
            "therapy": {
                "id": 918,
                "therapyName": "SNS-314",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9606,
                    "pubMedId": 28427193,
                    "title": "Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28427193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27721,
            "profileName": "AURKB positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27730,
            "profileName": "AURKA pos AURKB pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}